Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
A2CJ06
UPID:
DYTN_HUMAN
Alternative names:
-
Alternative UPACC:
A2CJ06
Background:
Dystrotelin, encoded by the gene with the accession number A2CJ06, plays a crucial role in cellular structure and function. Its precise biological activities and mechanisms of action are subjects of ongoing research, highlighting its importance in cellular biology.
Therapeutic significance:
Understanding the role of Dystrotelin could open doors to potential therapeutic strategies. Its involvement in cellular processes makes it a key target for drug discovery, aiming to address diseases at their molecular roots.